Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) Target Price at $9.33

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.3333.

SABS has been the subject of a number of research analyst reports. HC Wainwright reduced their target price on SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SAB Biotherapeutics in a report on Tuesday, October 14th. Leerink Partners began coverage on SAB Biotherapeutics in a report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Wall Street Zen raised SAB Biotherapeutics to a “sell” rating in a report on Saturday, September 20th.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock opened at $3.00 on Wednesday. The business has a 50 day simple moving average of $2.24 and a two-hundred day simple moving average of $2.01. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $6.60. The stock has a market capitalization of $31.23 million, a P/E ratio of -0.75 and a beta of 0.54. The company has a debt-to-equity ratio of 0.27, a current ratio of 0.87 and a quick ratio of 0.87.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Thursday, August 7th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27). As a group, analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Silver Oak Securities Incorporated bought a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,188 shares of the company’s stock, valued at approximately $30,000. Silver Oak Securities Incorporated owned about 0.22% of SAB Biotherapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.